

RA Declarations of interest register

Stephen Ward (Chair)

Date	Item declared	Classification	Action taken
Initial declaration	None declared.	-	-
14/09/16	GC1: No new interests declared.	-	-
07/11/16	GC2: No new interests declared.	-	-
19/12/16	GC3: No new interests declared.	-	-
30/01/17	GC4: No new interests declared.	-	-
07/03/17	GC5: No new interests declared.	-	-
21/04/17	GC6: No new interests declared.	-	-
30/05/17	GC7: No new interests declared.	-	-
05/07/17	GC8: No new interests declared.	-	-
12/09/17	GC9: Invited speaker EFIC (European Pain Federation) scientific meeting Copenhagen Sept 2017. Travel and accommodation reimbursed. No honorarium. Presentations: 1. Chair: session on interventional, pharmacological and multimodal treatment for back pain 2. Plenary lecture: low back pain guidelines for Europe 3. Refresher course lecture on back and neck pain.	Non-personal financial non-specific	Declare and participate
16/10/17	GC10: No new interests declared.	-	-

Ailsa Bosworth

Date	Item declared	Classification	Action taken
Initial declaration	Chief executive of NRAS. NRAS receives educational grants from industry (AbbVie, Eli Lilly, Medac, Merck, Pfizer, Roche, Sandoz, and UCB). NRAS caps its income from industry at no more than 15% of total income. In recent years, the amounts received have been less than this.	Non-personal, financial, non-specific	Declare and participate
14/09/16	GC1: Apologies sent.	-	-
07/11/16	GC2: No new interests declared.	-	-
19/12/16	GC3: No new interests declared.	-	-

Date	Item declared	Classification	Action taken
30/01/17	GC4: Funding 'in kind' from Sandoz for video to be made in March. This was not paid.	Non-personal financial non-specific	Declare and participate
07/03/17	GC5: No new interests declared.	-	-
21/04/17	GC6: No new interests declared.	-	-
30/05/17	GC7: No new interests declared.	-	-
05/07/17	GC8: No new interests declared.	-	-
12/09/17	GC9: Apologies sent.	-	-
16/10/17	GC10: NRAS received honoraria for AB presentation at UK Pharmacy conference on 1/11/17.	Non-personal financial non-specific	Declare and participate

Victoria Chamberlain

Date	Item declared	Classification	Action taken
Initial declaration	Past Trustee and Board member arthritis and Musculoskeletal alliance – resigned July 2016.	Personal, non-financial, specific	Declare and participate
	Nurse Advisor National Rheumatoid Arthritis Alliance.	Personal, non-financial, specific	Declare and participate
14/09/16	GC1: No new interests declared.	-	-
07/11/16	GC2: No new interests declared.	-	-
19/12/16	GC3: No new interests declared.	-	-
30/01/17	GC4: Apologies sent.	-	-
07/03/17	GC5: No new interests declared.	-	-
21/04/17	GC6: No new interests declared.	-	-
30/05/17	GC7: Apologies sent.	-	-
05/07/17	GC8: No new interests declared.	-	-
12/09/17	GC9: No new interests declared.	-	-
16/10/17	GC10: Apologies sent.	-	-

Jennie Jones

Date	Item declared	Classification	Action taken
Initial declaration	Trustee for NRAS. NRAS receives educational grants from industry (AbbVie, Eli Lilly, Medac, Merck, Pfizer, Roche, Sandoz and UCB). NRAS caps its income from industry at no more	Non-personal, financial, non-specific	Declare and participate

Date	Item declared	Classification	Action taken
	than 15% of total income. In recent years the amounts received have been less than this.		

	Holds 40 GlaxoSmithKline shares worth approximately £580 as part of my SIPP.	Personal, financial, specific	Agreed to sell shares on appointment.
14/09/16	GC1: No new interests declared.	-	-
07/11/16	GC2: No new interests declared.	-	-
19/12/16	GC3: No new interests declared.	-	-
30/01/17	GC4: No new interests declared.	-	-
07/03/17	GC5: No new interests declared.	-	-
21/04/17	GC6: No new interests declared.	-	-
30/05/17	GC7: No new interests declared.	-	-
05/07/17	GC8: No new interests declared.	-	-
12/09/17	GC9: No new interests declared.	-	-
16/10/17	GC10: No new interests declared.	-	-

Bruce Kirkham

Date	Item declared	Classification	Action taken
Initial declaration	<p>Advisory boards attended:</p> <ol style="list-style-type: none"> Novartis: secukinumab anti-IL-17 therapy in psoriatic arthritis - European meeting July 2016 Lilly: Scientific advisor for anti-IL-17 therapy in psoriatic arthritis, ixekizumab - Global Scientific Advisory Board June 2016 Lilly: Baricitinib as potential therapy in RA - Global Advisory Board July 2016 Sandoz: Biosimilar development in RA - UK advisory board February 2016 	1–4: Personal, financial, non-specific	1–4: Declare and participate
	<p>Speaker Bureaus for:</p> <ol style="list-style-type: none"> Novartis (psoriatic arthritis) - Last meeting July 2016 Janssen (psoriatic arthritis) - Last meeting will be September 2016 Bristol Myer Squibb - Last meeting September 2015 	1–3: Personal, financial, non-specific	1–3: Declare and participate
	<p>Clinical trial work (all contracts are with Guy's & St Thomas' Hospital BK is a PI or CI):</p> <ol style="list-style-type: none"> Lilly RA studies in long-term extension. UK chief Investigator since baricitinib Phase III studies began in 2013, all now in long-term extension Phase, PI at my site for 3 studies, which finish in 2 years 	<ol style="list-style-type: none"> Non-personal, financial, non-specific Non-personal, financial, non- 	<ol style="list-style-type: none"> Declare and participate Declare and participate

Date	Item declared	Classification	Action taken
	2. Novartis (secukinumab in psoriatic arthritis) UK Chief Investigator for one secukinumab study in PsA and one in AS, PI at my site for 3 secukinumab studies in psoriatic arthritis, beginning in 2012, planned finish in 2 years.	specific	
	Partnership Research Support for Investigator initiated studies (IIS). All these contracts are with Guy's & St Thomas' Hospital, BK is PI or CI. IIS arrangements are that the data is owned by the investigator and published in peer reviews publications: 1. AbbVie - Our RA Centre database was initially set up in 2006 with charitable funds. This large database of routine practice needs funds to support analysis. This project finishes in November 2016. 2. Roche (RA Centre database analysis support) - As above, analysis of RA Centre database, this project finishes in October 2016. 3. Novartis, basic science in psoriatic arthritis. Study exploring IL-17 biology in psoriatic arthritis in partnership with my university King's College London colleagues, no therapies included, project finishes in May 2017.	1–3: Non-personal, financial, non-specific	1–3: Declare and participate
14/09/16	GC1: No new interests	-	-
07/11/16	GC2: Participant at 2016 American College of Rheumatology Meeting. AbbVie Limited paid airfare, registration and hotel expenses.	Travel, accommodation and attendance expenses only	Declare and participate
19/12/16	GC3: Attendance and participation presenting to the PSANO meeting Oslo (Psoriatic arthritis) 20 January 2017 supported by Novartis Norway = airfare and honorarium.	Non-personal, financial, specific	Declare and participate
30/01/17	GC4: Institutional funding received by Guy's and St Thomas' NHS Foundation Trust Rheumatology Department in conjunction with Keele University from Eli Lilly, Ltd. to support an investigator partnership analysis of RA uses of routine care. BK is PI.	Non-personal, financial, non-specific	Declare and participate
07/03/17	GC5: No new interests declared.	-	-
21/04/17	GC6: Apologies sent.	-	-
30/05/17	GC7: Targeted Therapies meeting, Nice, 27–30 March, Funded by Universities of Vienna, Leiden and Erlangen, they are supported by non-directed educational grants from pharmaceutical companies, including AbbVie, Astra-Zeneca, Chugai, Lilly, Nippon Pharma, and Pfizer. I received travel and hotel accommodation, Honorarium is paid to Guys & St Thomas NHS Foundation Trust.	Non-personal, financial, non-specific	Declare and participate
	Participant in Novartis sponsored debate on Psoriatic Arthritis, Wed 26 April at the British Society of Rheumatology conference – I receive travel and hotel accommodation, Honorarium is paid to Guys & St Thomas NHS Foundation Trust.	Non-personal, financial, non-specific	Declare and participate
05/07/17	GC8: No new interests declared.	-	-

Date	Item declared	Classification	Action taken
12/09/17	GC9: Attendance at the European Academy of Dermatology Congress to participate in a Symposium sponsored by Novartis Pharmaceuticals, entitled 'Early Intervention and Disease Modification: Next Steps in Psoriasis'. Thursday 14 September. Transport paid by Novartis, honorarium paid to Guy's & St Thomas' NHS Foundation Trust.	Non-personal financial non-specific	Declare and participate
16/10/17	GC10: Advisory Board attendance Novartis Pharmaceuticals Enthesitis in Psoriatic Arthritis. Airfare paid, Honorarium to Hospital	Non-personal, financial, non-specific	Declare and participate

Hilary McKee

Date	Item declared	Classification	Action taken
Initial declaration	Educational support received from Pfizer, UCB, AbbVie	Personal financial non-specific	Declare and participate
	Honoraria for advisory boards or speaker fees received from Pfizer, AbbVie, Sandoz	Non-personal financial non-specific	Declare and participate

14/09/16	GC1: No new interests declared.	-	-
07/11/16	GC2: No new interests declared.	-	-
19/12/16	GC3: No new interests declared.	-	-
30/01/17	GC4: No new interests declared.	-	-
07/03/17	GC5: AbbVie sponsored attendance at BSR Birmingham April 2017; AbbVie to pay registration fee and accommodation	Non-personal financial non-specific	Declare and participate
21/04/17	GC6: No new interests declared.	-	-
30/05/17	GC7: No new interests declared.	-	-
05/07/17	GC8: No new interests declared.	-	-
12/09/17	GC9: 3rd Oct – 2 lectures: Polypharmacy and the rheumatology patient. Honorarium paid by Bristol Myers	Personal financial non-specific	Declare and participate
	12th Oct – Future of specialist pharmacists in immunology Chair and Speak. Honorarium paid by AbbVie.	Personal financial non-specific	Declare and participate
16/10/17	GC10: Apologies sent.	-	-

Frank McKenna

Date	Item declared	Classification	Action taken
Initial declaration	Current investigator for etanercept biosimilar (Sandoz) and attendance at one advisory board related to the compound.	Non-personal, financial, non-specific	Declare and participate
	Honorarium for attendance at a Sanofi advisory board in January 2016 on biosimilar etanercept in development.	Personal, financial, non-specific	Declare and participate
14/09/16	GC1: Gave a lecture at a satellite meeting at a EULAR 2016 conference sponsored by Janssen in June. An honorarium was received.	Personal, financial, non-specific	Declare and participate
07/11/16	GC2: No new interests declared.	-	-
19/12/16	GC3: No new interests declared.	-	-
30/01/17	GC4: No new interests declared.	-	-
07/03/17	GC5: No new interests declared.	-	-
21/04/17	GC6: No new interests declared.	-	-
30/05/17	GC7: No new interests declared.	-	-
05/07/17	GC8: No new interests declared.	-	-

Date	Item declared	Classification	Action taken
12/09/17	GC9: Honorarium for attending 'Medical Education Therapy Area Steering Committee for RA' Janssen-Cilag Ltd. 1 Sept 2017 (Related to invited lecture on depression in RA given at Janssen satellite in EULAR 2016 – declared in 2016)	Personal, financial, non-specific	Declare and participate
16/10/17	GC10: No new interests declared.	-	-

Anupama Nandagudi

Date	Item declared	Classification	Action taken
Initial declaration	Teaching for community pharmacy - Vitamin D - £350 from Internis	Personal, financial, non-specific	Declare and participate
	Teaching for GPs - Osteoporosis - A silent disease - £350 from Internis	Personal, financial, non-specific	Declare and participate
	Vertebral fractures talk - £250 from Lilly	Personal, financial, non-specific	Declare and participate
	Principal investigator: 1. OUTPASS, ABRISK, RUDY, GCA consortia, DARA, PERSIST, Genetic analysis for SLE and GWAS - Portfolio studies 2. SPIRIT psoriatic arthritis study funded by Lilly	1. Non-personal, non-financial, non-specific 2. Non-personal, financial, non-specific	1. Declare and participate 2. Declare and participate
	Co-investigator: 1. EMBRACE (which involved belimumab) – funded by GSK 2. R4RA, STRAP, Therapist, Titrator, APIPRA, BSRBR, BSPAR, BILAG, BFOF, UKIVAS, DCVAS, Myositis genetics and ankylosing spondylitis genetics - Portfolio studies	1. Non-personal, financial, non-specific 2. Non-personal, non-financial, non-specific	1. Declare and participate 2. Declare and participate
14/09/16	GC1: Apologies sent.	-	-
07/11/16	GC2: 1. IMS market research: use of biologics in RA (£75; reimbursed) 2. Genactis market research: RA treatment especially biologics (£200; reimbursed) 3. Market research: Ankylosing spondylitis (AS), Lupus (~£100)	1–3: Personal, financial, non-specific	Declare and participate
			Declare and participate
			Declare and participate
19/12/16	GC3: 1. Honorarium for articular fracture £250. 2. IMS Health – market research. £75.	1–2: Personal, financial, non-specific	Declare and participate
			Declare and participate
30/01/17	GC4: 1. Received funding for a talk on osteoporosis to be given locally to pharmacists and GPs. 2. IMS – Market research on drug rep interactions £25. 3. Market research – systemic sclerosis and interstitial lung disease (ILD) – £75.	1–3: Personal, financial, non-specific	Declare and participate
			Declare and participate
			Declare and participate

Date	Item declared	Classification	Action taken
07/03/17	GC5: 1. IMS company – Market research involving meetings – £25 2. Genactis company – Biologic treatment in RA – £160 3. Osteoporosis talk to local GPs – Internis company – £350 4. Attended the LEAP meeting-Novartis – They paid for the meeting, food and travel.	1–4:Personal, financial, non-specific	Declare and participate Declare and participate Declare and participate Declare and participate
21/04/17	GC6: 1. IMS-Drug representatives interaction – Market research 2. M3 Global research – Biologic use – Market research 3. Sermo-Biologic use in RA, psoriatic arthritis and axial spondyloarthritis – Market research	Personal, financial, non-specific Personal, financial, non-specific Personal, financial, non-specific	Declare and participate Declare and participate Declare and participate
30/05/17	GC7: No new interests declared.	-	-
05/07/17	GC8: No new interests declared.	-	-
12/09/17	GC9: No new interests declared.	-	-
16/10/17	GC10: No new interests declared.	-	-

Benjamin Parker

Date	Item declared	Classification	Action taken
Initial declaration	Genzyme funding to University of Manchester for study of neurocognitive function in systemic lupus erythematosus (2013-16; co-applicant) expires March 2017.	Personal, financial, non-specific	Declare and participate
	Honoraria for advisory boards: 1. UCB Pharma - one-off event April 2016 2. AbbVie - open ended - no further events planned	1. Personal, financial, non-specific 2. Personal, financial, non-specific	1. Declare and participate 2. Declare and participate
	Speaker honoraria from: 1. AbbVie - intermittent, no further events planned 2. Pfizer - intermittent, event scheduled for November 2016 3. BMS - intermittent, no further events planned	1–3: Personal, financial, non-specific	1–3: Declare and participate
	Travel funded by AbbVie (American College Rheumatology, Washington DC, November 2016) single event.	Travel expenses only	None
14/09/16	GC1: Sub-investigator - A randomised open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for response-resistance to rituximab vs	Non-personal, financial, non-specific	Declare and participate

Date	Item declared	Classification	Action taken
	tocilizumab in RA (R4-RA). Sponsored by Queen Mary University.		
	GC1: Sub-investigator - Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept. Sponsored by BMS.	Non-personal, financial, non-specific	Declare and participate
	GC1: Sub-investigator - A study to Investigate the role of Interleukin Seventeen (IL-17) and Th17 pathway activation in RA patients with inadequate response to anti-TNF-alpha therapies – “THERAPIST” (Th17 Responses Evaluated in RA Patients on Inhibitors of TNF α). Sponsored by Queen Mary University.	Non-personal, financial, non-specific	Declare and participate
	GC1: Sub-investigator - A non-interventional study to assess the effectiveness of certolizumab pegol in patients with axial spondyloarthritis in daily practice. Sponsored by UCB BIOPHARMA.	Non-personal, financial, non-specific	Declare and participate
	GC1: Sub-investigator - An open label randomised multicentre controlled trial of rituximab and MMF without oral steroids for the treatment of lupus nephritis. Sponsored by Imperial College London.	Non-personal, financial, non-specific	Declare and participate
07/11/16	GC2: No new interests declared.	-	-
19/12/16	GC3: Apologies sent.	-	-
30/01/17	GC4: December 2016 – Chair of ‘Cosentyx and Psoriatic arthritis – AXSPA’ meeting; sponsored by Novartis. Honorarium received.	Non-personal, financial, non-specific	Declare and participate
	January 2017 – Chair of ‘Impact of DevoManc on Rheumatology Services in Greater Manchester’; sponsored by Pfizer. Honorarium received.	Non-personal, financial, non-specific	Declare and participate
07/03/17	GC5: No new interests declared.	-	-
21/04/17	GC6: No new interests declared.	-	-
30/05/17	GC7: No new interests declared.	-	-
05/07/17	GC8: No new interests declared.	-	-
12/09/17	GC9: No new interests declared.	-	-
16/10/17	GC10: Speaker at ‘Specialist Pharmacists in Immunology’ meeting sponsored by Abbvie Topic: 1. role of specialist pharmacist in immunology 2. AxSpA case presentation Travel reimbursed (train to London) and honoraria donated to hospital	Non-personal, financial, non-specific	Declare and participate

Heidi Siddle

Date	Item declared	Classification	Action taken
------	---------------	----------------	--------------

Date	Item declared	Classification	Action taken
Initial declaration	NIHR funded Clinical Lectureship - Tight control of inflammatory foot and ankle disease in patients with rheumatoid arthritis: March 2015 – February 2019	Personal, financial, non-specific	Declare and participate
	Funds received from EULAR to develop recommendations for non-medical health professional using musculoskeletal ultrasound: July 2015 – October 2016	Personal, financial, non-specific	Declare and participate
14/09/16	GC1: Co-editor for a book “The foot and ankle in rheumatology” due for publication 2018 by Oxford University Press.	Personal, financial, non-specific	Declare and participate
07/11/16	GC2: Invited to lead a breakout workshop on podiatry at the 2017 UK GRAPPA workshop on Friday 27 January 2017. Meeting sponsored by Janssen UK, honorarium received.	Personal, non-financial, non-specific	Declare and participate
19/12/16	GC3: Apologies sent.	-	-
30/01/17	GC4: Speaker/teacher British Society for Rheumatology (BSR) Foot and Ankle course. 16–17 March, Leeds. Honorarium received from BSR.	Non-personal financial specific	Declare and participate
07/03/17	GC5: No new interests declared.	-	-
21/04/17	GC6: No new interests declared.	-	-
30/05/17	GC7: No new interests declared.	-	-
05/07/17	GC8: No new interests declared.	-	-
12/09/17	GC9: Chairing ‘ultrasound in podiatry’ session at College of Podiatry Annual conference on 16 November 2017. I am not receiving any expenses or honorarium.	Non-personal non-financial non-specific	Declare and participate
16/10/17	GC10: No new interests declared.	-	-

Louise Warburton

Date	Item declared	Classification	Action taken
Initial declaration	Has written a chapter in a book on osteoporosis, due to be published	Personal, non-financial, non-specific	Declare and participate
	Trustee of the Arthritis and Musculoskeletal Alliance (ARMA), which receives funding from industry.	Non-personal, financial, non-specific	Declare and participate
14/09/16	GC1: Attending BRITSpA 2016 Meeting (incorporating the New Perspectives in Research and Management in AS) in September.	Travel and accommodation only	Declare and participate
07/11/16	GC2: Speaking at the NAPC’s Best Practice conference on low back pain. 19–20 October in Birmingham.	Personal, non-financial, non-specific (travel and accommodation only)	Declare and participate
	The organisers provide travel expenses only.		
19/12/16	GC3: No new interests declared.	-	-

Date	Item declared	Classification	Action taken
30/01/17	GC4: Attended EULAR meeting in Zurich on 25/01/2017 to produce guidelines on exercise in osteoarthritis and inflammatory arthritis. Flight paid for.	Travel only	Declare and participate
07/03/17	GC5: No new interests declared.	-	-
21/04/17	GC6: Invited to join a Spondyloarthritis Policy Initiative with Novartis; no remuneration provided.	Personal, non-financial, non-specific	Declare and participate
30/05/17	GC7: No new interests declared.	-	-
05/07/17	GC8: No new interests declared.	-	-
12/09/17	GC9: No new interests declared.	-	-
16/10/17	GC10: Speaking about inflammatory arthritis at Best Practice conference at NEC Birmingham on 19.10.17. Organisers are Closer Still Media. Honorarium received.	Personal, financial, non-specific	Declare and participate

Amanda Isaac (Co-optee)

Date	Item declared	Classification	Action taken
Initial declaration	None declared.	-	-